Oriol Mirallas MD· @DrMirallas · X·· 15 小时前评分70
正文 · 原文
🔥 Presidential Symposium I #ESMO26
INTerpath-001: double-blind phase 3 study of intismeran (mRNA vaccine) + pembro as adjuvant therapy for resected stage IIB–IV #melanoma
✔️ RFS 82.2 vs 70% HR 0.58
✔️ DMFS 88.5 vs 80.2% HR 0.62
☣️ No increased risk of toxicity in the combination
✅🧫 mRNA Vaccine in adjuvant melanoma treatment together with anti-PD1
@OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @brunolarvol
👇🏽👇🏽
99 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：Oriol Mirallas MD · x.com